XOMA 2025 income, revenue jump on portfolio expansion, milestone payments
Overview
US biotech royalty aggregator's 2025 income and revenues rose 83% yr/yr to $52.1 mln
Net income for 2025 turned positive at $31.7 mln, up from a $13.8 mln loss in 2024
Company repurchased $16 mln of shares and completed seven acquisitions in 2025
Outlook
OJEMDA 2026 revenue guidance of $225 mln to $250 mln
Company expects several regulatory and clinical milestones in 2026, including EMA decisions and Phase 2/3 data
XOMA anticipates growing free cash flow in 2027 and beyond from portfolio diversification
Result Drivers
ROYALTY AND MILESTONE RECEIPTS - Co said higher income was primarily driven by increased royalties from VABYSMO and OJEMDA and milestone payments from Rezolute and Takeda
PORTFOLIO EXPANSION - Co added 22 assets and completed seven acquisitions, expanding its portfolio of royalty and milestone rights
BUSINESS DEVELOPMENT COSTS - Higher general and administrative expenses were mainly due to increased business development and deal-related costs and litigation expenses
Company press release: ID:nGNX8zbq35
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
FY EPS |
| $1.46 |
|
FY Net Income |
| $31.71 mln |
|
FY Operating Expenses |
| $40.77 mln |
|
FY Operating Income |
| $11.38 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the entertainment production peer group is "buy"
Wall Street's median 12-month price target for Xoma Royalty Corp is $58.00, about 114.8% above its March 17 closing price of $27.00
The stock recently traded at 91 times the next 12-month earnings vs. a P/E of 112 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
